SciLifeLab Drug Discovery Workshop Uppsala 1 June 2015 Nanna - - PowerPoint PPT Presentation

SciLifeLab Drug Discovery Workshop Uppsala 1 June 2015

Nanna Lüneborg Novo Seeds

• Seed arm of Novo A/S
• European seed investor with

Scandinavian focus

• Building companies through grants and

investments

• Evergreen fund structure supporting

follow-on investments

• Life science investor covering drugs,

devices and industrial biotech

Novo Seeds

Public

100% ownership

Large Investments

> 25% ownership > 70% share of votes > 25% ownership > 70% share of votes

Novo Seeds Novo Ventures

Private

Financial Investments

Private Public

Basic research grants Strategic centres

Novo Seeds A unique combination of grants and investments

to create biotech start-ups

Testing of interesting ideas IP analysis Commercial analysis PoC studies Business plan creation Setting the team Lead identification Prototype development Clinical PoC

Financial: up to USD 0.1 M Time: up to 12 months Exploratory pre-seed grants Pre-seed grants Seed investments Financial: up to USD 0.5 M Time: up to 18 months Financial: up to USD 12 M* Time: to exit

* May exceed $12M w board approval

Increased commitment to Scandinavian biotech start-ups

1 2 4 9 13 17 24 31 4 7 10 14 18 20 24

10 20 30 40 50 60 2007 2008 2009 2010 2011 2012 2013 2014

Pre-seed grants Seed investments No of grants and investments (cumulative)

3-4 new seed investments per year

Groundbreaking science

Potential to be a gamechanger

Credible founder team

Publication and career track record Entrepreneurial drive Commercial & academic

Feasible development plan

Value-adding PoC studies …that can be reached within scope of funding Access to relevant expertise

Strong IP position

What do we look for?

7

Novo Seeds – successfully growing projects into companies through our grant pipeline

RSK

NNF Novo Seeds

Exploratory pre- seed grant Startup seed investment Regional seed investment Series A/B investment Pre-seed grant

$444m BMS deal €20m Series B WT, BIVF Series A Wellcome Trust Translational Award

8

2008 Company founded with DKK 5 M from Novo Seeds and DKK 3.8 M from DSI Innovation 2010 Novo Seeds forms syndicate with Astellas, Merck Serono Ventures, Lundbeck Fond Emerge and SEEDCapital 2011 Collaboration agreement with AbbVie (USD 5 M) 2013 Series A of DKK 117 M 2013 Georges Gemayel appointed Chairman of BoD (ex. Roche, Genzyme, FoldRx) 2014 Kapil Dhingra appointed member of BoD (Algeta, Biovex) 2014 Nomination of clinical candidate EPT103182 2015 EpiTherapeutics acquired by Gilead in $65m upfront deal EPT103182 is effective in multiple myeloma Human MOLP6 xenograft

Company founded on seminal work of Professor Kristian Helin, BRIC, KU – a world leader in the field of epigenetics

Gilead Sciences Acquires EpiTherapeutics - Deal Adds Small Molecule Inhibitors against Targets Involved in Epigenetic Regulation

2009 2010

Novo Seeds awards pre-seed grant to Lund

University to study galectin-3 inhibitors in various animal models 2011 Company founded with SEK 2.4 M seed investment from Novo Seeds 2011 Novo Seeds forms syndicate with Merck Serono ventures, Sunstone Capital, SEED capital 2012 Series A of SEK 88 M 2014 October start of first human trial of TD139 2014 November $444m option deal with BMS to acquire company after Phase 1b

Galecto founders: Ulf Nilsson – organic chemist, LU. Pioneering small molecule galectin inhibitors Hakon Leffler – glycobiologist, LU. Discoverer of galectin Tariq Sethi – IPF clinical researcher, KCL. Professor in respiratory medicine, galectin-3 and fibrosis expert Hans Schambye – serial entrepreneur, engaged as project manager on pre-seed grant by Novo Seeds

Galectin-3 Novo Seeds engages biotech entrepreneur, Hans Schambye, to review a number of academic projects for commercialisation from Swedish Universities

Spinout from Karolinska Institute

Company founded in 2014 Healthcap, Novo Seeds, Industrifonden

42m SEK seed financing

Novel mechanism to target glioblastoma

Compelling animal data published in Cell, 2014

Lead candidate drug identified

Project matured in academia Developed by Chemical Biology Consortium Sweden

10

• an introduction
• Most common and

aggressive brain cancer

• Incidence: 50.000 new

cases per annum, US and EU

• High unmet need
• 5-year survival: 3%

Glioblastoma multiforme

Preclinical data:

compelling survival benefit in mice with xenograft of patient derived GBM cells All untreated animals die within weeks After 80 days, 6 of 8 treated animals still alive

Financing supports clinical development:

Preclinical safety studies File IND First in man to start 2016

11

• an introduction

Treatment: 20 mg/kg Vacq-1, oral, 5 days, from day 14

Company funded to exit

Syndicate in place to fund pivotal trial

The 2015 Seed Portfolio

Discovery Lead Optimisation Pre-Clinical Clinical Phase I Clinical Phase IIa C10 Pharma Anti-microbial Contera Pharma L-DOPA induced dyskinesia Aros Pharma Pain indications Acesion Pharma Atrial fibrillation Forendo Pharma Endometriosis RSPR Asthma Pcovery Anti-fungal EpiTherapeutics Cancer epigenetics Galecto Fibrosis Glionova Glioblastoma Avilex Neuroprotection Adenium Anti-microbial IO Biotech Immuno Oncology Lysogene Gene therapy Affinicon Macrophage targeted drugs MinervaX GBS vaccine PoC Prototype Development PMA/510k Sales

Biosyntia Synthetic biology

Reapplix Wound care Denator Protein stabilization

2 December 2014

Small molecules Proteins / peptides Other

012

New in 2014/5 Exit in 2014/5

13

Regional Corporate/Strategic Financial

Our co-investors

InnoBio

Novo Seeds team 2015

Søren Møller, PhD

Managing Investment Director Post doc at Stanford University, CSO at Exiqon Head of Bioinformatics and Genomics at Novozymes A/S Denator, Reapplix, EpiTherapeutics smq@novo.dk

Bobby Soni, PhD

Investment Director PhD University of Virginia, Scientist/Project leader at Maxygen, BD at LEO Pharma Acesion, Avilex, RSPR bygs@novo.dk

Stephan Christgau, PhD

Investment Director Post doc at UCSF, Reserach scientist at Novo Nordisk, Project leader Nordic Bioscience, COO and VP at Osteologix Inc Adenium, ForEndo, Galecto, Lysogene scga@novo.dk

Nanna Lüneborg, PhD, MBA

Investment Director PhD UCL, MBA University of Cambridge, Associate, Apposite Capital, Research manager, Cancer Research UK Affinicon, MinervaX, Pcovery, Glionova, IO nllb@novo.dk

Annemette Hessels

Administrative Coordinator Business administration degree, experience from Ferring Pharmaceuticals aezh@novo.dk

Thank you